Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
No Study Results Posted
A Study to Compare the Bioequivalence of 50-mg Tapentadol (CG5503) Dose Administered as Two 50-mg Tablets Relative to One 100-mg Tablet
This study has been completed.
Study NCT01273532 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
First Received on January 7, 2011. Last Updated on March 12, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Interventions listed in this trial
tapentadol (CG5503) ER 100-mg TRF
tapentadol (CG5503) ER 50-mg TRF
Sponsors listed in this trial
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers